Product Description:
Alectinib is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Crizotinib. Alectinib as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Product Features:
| Product Name | Alecinix |
| Generic Name | Alectinib |
| Formulation | Capsule |
| Available Strength | 150 mg |
| Registrations | Available |
| Website | alecinix.com |
